Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Patient Resources
COVID-19 Patient Resource Center
Clinical Trials
Search Clinical Trials
Patient Notification System
What is Clinical Research?
Volunteering for a Clinical Trial
Understanding Informed Consent
Useful Resources
FDA Approved Drugs
Professional Resources
Research Center Profiles
Clinical Trial Listings
Market Research
FDA Approved Drugs
Training Guides
Books
Events
Newsletters
JobWatch
White Papers
Patient Education
SOPs
eCFR and Guidances
White Papers
Trial Listings
Advertise
COVID-19
iConnect
Sign In
Create Account
Sign Out
My Account
Home
» Regulatory Update
Looking to read the full article? Subscribe today!
Regulatory Update
October 1, 2019
FDA Releases Guidance on Drug Development for Fabry Disease
Upcoming Events
11
Feb
Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era
23
Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
26
Apr
MAGI's Clinical Research vConference â Spring 2021
Featured Products
Regenerative Medicine: Steps to Accelerate Development
Clinical Trial Agreements: A Guide to Key Words and Phrases
Featured Stories
Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources
Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites
2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say
COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts
Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials
The information you need to adapt your monitoring plan to changing times.
Learn More Here